A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
NCT ID: NCT00784693
Last Updated: 2021-04-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
48 participants
INTERVENTIONAL
2008-12-18
2010-04-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pain Associated With Endometriosis
NCT00758953
Safety and Efficacy Study of MT-2990 in Women With Endometriosis
NCT03840993
Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
NCT03481842
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
NCT03986944
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
NCT07100782
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tanezumab
Tanezumab
15 mg IV single dose
Placebo
Placebo
Placebo IV single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tanezumab
15 mg IV single dose
Placebo
Placebo IV single dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects should have regular menstrual cycle (21 - 35 days) and must be willing to use adequate contraception (2 forms of birth control, one of which must be a barrier method). Contraception is required throughout the study (screening to 16 weeks post treatment), even if subjects discontinue prematurely.
Exclusion Criteria
* Surgical treatment for endometriosis within last 6 months.
* Medical treatment for endometriosis other than combined oral contraceptive pill within the last 3 months
* Current use of the coil or progesterone only contraceptive (the combined oral contraceptive pill is allowed).
* Any history of malignant disease (cancer)
18 Years
49 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bay Area Physicians for Women
Mobile, Alabama, United States
Springhill Medical Center
Mobile, Alabama, United States
Wilmax Clinical Research
Mobile, Alabama, United States
Visions Clinical Research - Tucson
Tucson, Arizona, United States
Genesis Center for Clinical Research
San Diego, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Visions Clinical Research
Boynton Beach, Florida, United States
Nature Coast Clinical Research, LLC
Crystal River, Florida, United States
Jacksonville Center for Clnical Research
Jacksonville, Florida, United States
Advanced Women's Healthcare
West Palm Beach, Florida, United States
Comprehensive Clinical Trials, LLC
West Palm Beach, Florida, United States
Mount Vernon Clinical Research
Atlanta, Georgia, United States
Radiant Research
Overland Park, Kansas, United States
Women's Healthcare Group
Overland Park, Kansas, United States
N.E.C.C.R, Fall River LLC
Fall River, Massachusetts, United States
Beyer Research - Women's Health Care Specialists, PC
Paw Paw, Michigan, United States
Women's Clinic of Lincoln, PC
Lincoln, Nebraska, United States
Lyndhurst Clinical Research
Kernersville, North Carolina, United States
Lyndhurst Clinical Research
Winston-Salem, North Carolina, United States
Columbus Center for Women's Health Research
Columbus, Ohio, United States
Planned Parenthood of Arkansas and Eastern Oklahoma
Tulsa, Oklahoma, United States
Allegheny Pain Management
Altoona, Pennsylvania, United States
Greenville Hospital System University Medical Group, Department of OB/GYN
Greenville, South Carolina, United States
ClinSearch, LLC
Chattanooga, Tennessee, United States
Whitaker's Women Care
East Ridge, Tennessee, United States
Advances In Health, Inc.
Houston, Texas, United States
Allon Health Care
Houston, Texas, United States
Old Farm Obstetrics and Gynecology
Salt Lake City, Utah, United States
Salt Lake Research
Salt Lake City, Utah, United States
Women's Clinical Research Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENDOMETRIOSIS POC
Identifier Type: OTHER
Identifier Source: secondary_id
A4091023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.